MC Bonferoni, S Rossi, G Sandri, F Ferrari, E Gavini… - Pharmaceutics, 2019 - mdpi.com
The blood–brain barrier (BBB) plays a fundamental role in protecting the brain from toxic substances and therefore also controls and restricts the entry of therapeutic agents. The …
N Rapoport, KH Nam, R Gupta, Z Gao, P Mohan… - Journal of Controlled …, 2011 - Elsevier
Perfluorocarbon nanoemulsions can deliver lipophilic therapeutic agents to solid tumors and simultaneously provide for monitoring nanocarrier biodistribution via ultrasonography and/or …
P Mohan, N Rapoport - Molecular pharmaceutics, 2010 - ACS Publications
Doxorubicin (DOX) is one of the most commonly used chemotherapeutic drugs and is a popular research tool due to the inherent fluorescence of the DOX molecule. After DOX …
Recently, perfluorocarbon (PFC) nanodroplets were introduced as contrast agents for imaging and image-guided therapy. For example, in sonography, high-intensity ultrasound …
This review focuses on phase‐shift perfluorocarbon nanoemulsions whose action depends on an ultrasound‐triggered phase shift from a liquid to gas state. For drug‐loaded …
PS Sheeran, PA Dayton - Current pharmaceutical design, 2012 - ingentaconnect.com
Phase-change contrast agents (PCCAs) for ultrasound-based applications have resulted in novel ways of approaching diagnostic and therapeutic techniques beyond what is possible …
Lipid nanoemulsions (NEs), owing to their controllable size (20 to 500 nm), stability and biocompatibility, are now frequently used in various fields, such as food, cosmetics …
Because many tumors possess blood vessels permeable to particles with diameters of 200 nm, it is possible that submicron perfluorocarbon droplets could constitute a novel …
Acoustically activated submicron droplets of liquid perfluorocarbon are investigated as a new class of ultrasound contrast agent. In the liquid state, intravascular droplets can …